Diversified Consumer Services
Company Overview of The University of Texas M. D. Anderson Cancer Center
The University of Texas M. D. Anderson Cancer Center is an educational institution that offers undergraduate and research programs to physicians, biomedical scientists, and other health-care professionals. The departments include behavioral medicine, biochemistry and molecular biology, cancer biology program, cancer genomics core laboratory, molecular and cellular oncology, molecular genetics, molecular hematology and therapy, molecular therapeutics, and molecular pathology. The University of Texas M. D. Anderson Cancer Center was founded in 1941 as Texas State Cancer Hospital and the Division of Cancer Research and changed its name to M. D. Anderson Hospital for Cancer Research of The Unive...
1515 Holcombe Boulevard
Houston, TX 77030
Founded in 1989
Key Executives for The University of Texas M. D. Anderson Cancer Center
Executive Vice President and Physician-In-Chief
Chairman of Department of Health Disparities Research
Vice President and Head of the Division of Pharmacy
Compensation as of Fiscal Year 2016.
The University of Texas M. D. Anderson Cancer Center Key Developments
Golden Meditech Holdings Limited and MD Anderson Cancer Center Team Up to Create Cellenkos, Inc
Sep 19 16
Golden Meditech Holdings Limited and The University of Texas announced the creation of Cellenkos Inc. a start-up enterprise focused on umbilical cord blood derived T-regulatory cellular therapies. Cellenkos, to be based in Houston, is funded with an initial investment of USD 10 million with warrants to purchase an additional USD 10 million worth of shares by Golden Meditech and an independent strategic investor. The agreement covers technologies arising from the laboratory investigations of Simrit Parmar, M.D., associate professor in the Department of Stem Cell Transplantation and Cellular Therapy at MD Anderson. Cellenkos will build on Dr. Parmar's existing and potential future pre-clinical and clinical research to develop various T-reg-based therapies for clinical use in treating autoimmune diseases where the patient's T-reg cells are often defective and/or lower in number. These chronic and morbid diseases require long-term treatment with drugs that suppress the immune system that often have adverse side effects. Adoptive therapy with cord blood derived T-reg cells has the potential to replenish the immune system and impact patient care by providing novel, non-pharmacologic options.
Scripps Health and The University of Texas MD Anderson Cancer Center Announce Partnership Agreement to Create Scripps MD Anderson Cancer Center
Sep 8 16
Scripps Health and The University of Texas MD Anderson Cancer Center have reached a partnership agreement to create Scripps MD Anderson Cancer Center, a comprehensive and clinically integrated cancer care program in San Diego. Through this partnership, Scripps MD Anderson is part of MD Anderson Cancer Network, a global collaborative network of hospitals and health care systems dedicated to MD Anderson's mission to end cancer globally. The collaboration allows Scripps to combine its expertise with MD Anderson's knowledge and capabilities for Southern California, covering eight counties from Santa Barbara to the US-Mexico border. It will offer patients access to MD Anderson's world-renowned treatment protocols, standards of care, extensive clinical trials and translational research. Patients also will have access to comprehensive cancer care, including medical oncology, radiation oncology, surgical oncology, pathology, laboratory and diagnostic imaging, as well as other clinical and support services. Close collaboration between the two organizations will be a hallmark of the new Scripps MD Anderson. MD Anderson Cancer Center will bring a multidisciplinary approach to local cancer patients and provide a new dimension of innovative care and treatment options. Through joint tumor boards, MD Anderson also will provide opinions for diagnosis and treatment. The program will offer a patient-centered approach to care, with multidisciplinary teams of oncology specialists supporting patients and families in making informed, evidence-based medical decisions. It will also offer an array of patient support services, including genetic counseling, nurse navigation, integrative medicine, palliative care, imaging services and social worker assistance in one convenient, patient-friendly environment.
BioLineRx Has Signs Collaboration Agreement with the University of Texas MD Anderson Cancer Center
Aug 8 16
BioLineRx has signed a collaboration agreement with The University of Texas MD Anderson Cancer Center to investigate the combination of BL-8040 with Keytruda (pembrolizumab) in pancreatic cancer. The study will be part of a strategic clinical research collaboration between Merck (in the U.S. and Canada) and MD Anderson Cancer Center aimed at evaluating Keytruda, Merck's anti-PD-1 therapy, in combination with various treatments and novel drugs.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|